ATE242639T1 - Morphogen induzierte nerven wiederherstellung und wiedergutmachung. - Google Patents

Morphogen induzierte nerven wiederherstellung und wiedergutmachung.

Info

Publication number
ATE242639T1
ATE242639T1 AT93918560T AT93918560T ATE242639T1 AT E242639 T1 ATE242639 T1 AT E242639T1 AT 93918560 T AT93918560 T AT 93918560T AT 93918560 T AT93918560 T AT 93918560T AT E242639 T1 ATE242639 T1 AT E242639T1
Authority
AT
Austria
Prior art keywords
neurons
mammal
stimulating
repair
morphogenely
Prior art date
Application number
AT93918560T
Other languages
English (en)
Inventor
David C Rueger
Thangavel Kuberasampath
Hermann Oppermann
Engin Ozkaynak
Roy H L Pang
Charles M Cohen
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27363454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE242639(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of ATE242639T1 publication Critical patent/ATE242639T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/32—Materials or treatment for tissue regeneration for nerve reconstruction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
AT93918560T 1992-07-31 1993-07-29 Morphogen induzierte nerven wiederherstellung und wiedergutmachung. ATE242639T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92281392A 1992-07-31 1992-07-31
US2933593A 1993-03-04 1993-03-04
US4051093A 1993-03-31 1993-03-31
PCT/US1993/007231 WO1994003200A1 (en) 1992-07-31 1993-07-29 Morphogen-induced nerve regeneration and repair

Publications (1)

Publication Number Publication Date
ATE242639T1 true ATE242639T1 (de) 2003-06-15

Family

ID=27363454

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93918560T ATE242639T1 (de) 1992-07-31 1993-07-29 Morphogen induzierte nerven wiederherstellung und wiedergutmachung.

Country Status (10)

Country Link
EP (1) EP0653942B2 (de)
JP (3) JP4344012B2 (de)
AT (1) ATE242639T1 (de)
AU (1) AU681594B2 (de)
CA (1) CA2141554C (de)
DE (1) DE69333040T3 (de)
DK (1) DK0653942T3 (de)
ES (1) ES2201059T5 (de)
PT (1) PT653942E (de)
WO (1) WO1994003200A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723698B2 (en) 1991-03-11 2004-04-20 Curis, Inc. Methods and compositions for the treatment of motor neuron injury and neuropathy
US6495513B1 (en) 1991-03-11 2002-12-17 Curis, Inc. Morphogen-enhanced survival and repair of neural cells
US6506729B1 (en) 1991-03-11 2003-01-14 Curis, Inc. Methods and compositions for the treatment and prevention of Parkinson's disease
DK0653942T3 (da) * 1992-07-31 2003-10-20 Curis Inc Morphogen-induceret nerve-regenerering og -reparation
WO1994006447A2 (en) * 1992-09-15 1994-03-31 Creative Biomolecules, Inc. 60a protein-induced morphogenesis
DK0698094T3 (da) 1993-05-12 2004-05-03 Inst Genetics Llc BMP-11-sammensætninger
PT716610E (pt) * 1993-08-26 2006-08-31 Genetics Inst Llc Proteinas morfogeneticas dos ossos de seres humanos para utilizacao em regeneracao neural
US5669407A (en) * 1994-03-24 1997-09-23 Masco Corporation Of Indiana Compression cartridge for a faucet valve assembly
WO1996030038A1 (en) * 1995-03-29 1996-10-03 The Rockefeller University Peptide growth factor having epidermal inducing activity
EP0904093A4 (de) * 1996-03-22 2004-11-17 Gen Hospital Corp Die verabreichung von wachstumsfaktor-polypeptiden nach einer ischemie des zentralen nervensystems oder einem trauma
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5928940A (en) * 1996-09-24 1999-07-27 Creative Biomolecules, Inc. Morphogen-responsive signal transducer and methods of use thereof
AU4726597A (en) * 1996-10-31 1998-05-22 Nippon Shinyaku Co. Ltd. Cranial nerve cell protectives
WO1998020889A1 (en) * 1996-11-15 1998-05-22 Creative Biomolecules Inc Morphogen peptide-induced regeneration of sense perceptory tissues
JP5033276B2 (ja) * 1997-05-05 2012-09-26 ストライカー コーポレイション 急性腎不全の治療
JP2001526788A (ja) 1997-05-30 2001-12-18 クリエイティブ バイオモレキュールズ，インコーポレイテッド 組織形態形成および活性を評価するための方法
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7147839B2 (en) * 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
WO2000029012A2 (en) † 1998-11-13 2000-05-25 Curis, Inc. Methods of alleviating cancer symptoms
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
AU2003247551C1 (en) 2002-06-17 2010-12-09 Thrasos Innovation, Inc. Single domain TDF-related compounds and analogs thereof
JP4971149B2 (ja) 2004-06-17 2012-07-11 スラソス セラピューティックス インコーポレーテッド Ｔｄｆ関連化合物およびその類似体
CN101031645B (zh) * 2004-06-23 2011-06-08 组织基因股份有限公司 神经再生
HUE026634T2 (en) 2005-09-20 2016-07-28 Thrasos Innovation Inc TDF-related compounds and analogues thereof
ES2474194T3 (es) 2008-02-13 2014-07-08 Keith Hruska PMO-7 para su uso en el tratamiento de la hiperplasia de la neo�ntima
US20110002897A1 (en) 2009-06-11 2011-01-06 Burnham Institute For Medical Research Directed differentiation of stem cells
MA47163A (fr) * 2016-12-16 2019-11-06 Biogen Ma Inc Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011366A1 (en) * 1989-03-28 1990-10-04 Genetics Institute, Inc. Osteoinductive compositions
WO1989009788A2 (en) * 1988-04-08 1989-10-19 Creative Biomolecules, Inc. Biosynthetic osteogenic proteins and osteogenic devices containing them
DE69131580T2 (de) * 1990-06-15 2000-01-13 Carnegie Institution Of Washington, Washington GDF-1 und UOG1 Proteine
EP0575555B1 (de) * 1991-03-11 2001-07-18 Curis, Inc. Protein-induzierende morphogenese
WO1993009229A1 (en) * 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
DK0653942T3 (da) * 1992-07-31 2003-10-20 Curis Inc Morphogen-induceret nerve-regenerering og -reparation

Also Published As

Publication number Publication date
AU4797193A (en) 1994-03-03
WO1994003200A1 (en) 1994-02-17
AU681594B2 (en) 1997-09-04
DE69333040T3 (de) 2007-10-11
JP2005287512A (ja) 2005-10-20
EP0653942B2 (de) 2007-03-07
JP4344012B2 (ja) 2009-10-14
CA2141554C (en) 2003-02-11
DE69333040T2 (de) 2004-05-06
CA2141554A1 (en) 1994-02-17
JP2009227679A (ja) 2009-10-08
EP0653942B1 (de) 2003-06-11
DK0653942T3 (da) 2003-10-20
DE69333040D1 (de) 2003-07-17
EP0653942A1 (de) 1995-05-24
PT653942E (pt) 2003-11-28
ES2201059T3 (es) 2004-03-16
ES2201059T5 (es) 2007-11-01
JPH07509721A (ja) 1995-10-26

Similar Documents

Publication Publication Date Title
ATE242639T1 (de) Morphogen induzierte nerven wiederherstellung und wiedergutmachung.
DK0670729T3 (da) Anvendelse af insulin-lignende vækstfaktorer og analoger til behandling af retinale nervesygdomme
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
DK1039802T3 (da) Transdermal terapeutisk anordning med capsicin og capsaicinanaloger
DE58906649D1 (de) Implantierbares medizinisches Gerät mit Mitteln zum Stimulieren von Gewebekontraktionen mit einstellbarer Stimulationsintensität und Verfahren zum Betrieb eines solchen Gerätes.
ATE339956T1 (de) Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin
ATE434975T1 (de) Vorrichtung und verfahren zur repositionierung von patienten
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
FR2760369B1 (fr) Stimulateur cardiaque multisites pour le traitement des insuffisances cardiaques par stimulation
ES2114073T3 (es) Regeneracion del higado inducida por morfogenes.
DE3875866D1 (de) Sulfonamidolphenyl-derivate und diese enthaltende therapeutische und vorbeugend wirkende mittel gegen arrhythmie.
Lund et al. Cortical reorganization and deafferentation in adult macaques
Lee et al. Nerve growth factor expression in stroke induced rats after shock wave
NO20010390L (no) Behandling av angstsykdommer
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
DE69205307D1 (de) Vorrichtung zum Behandeln von Akupunkturpunkten mittels elektrischen Feldern und Medikamentenionen.
CY1108922T1 (el) Θεραπεια μελανωματος
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
ATE247468T1 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
RU99115126A (ru) Способ лечения и восстановления трудоспособности больных общесоматическими заболеваниями
RU93057107A (ru) Способ лечения рефлюкс-эзофагита у больных бронхиальной астмой с помощью инфракрасного лазера

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0653942

Country of ref document: EP

REN Ceased due to non-payment of the annual fee